Business Description
Innoviva Inc
NAICS : 325412
SIC : 2834
ISIN : US88338T1043
Total Employee Number:
159Description
Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.15 | |||||
Equity-to-Asset | 0.72 | |||||
Debt-to-Equity | 0.22 | |||||
Debt-to-EBITDA | 0.58 | |||||
Interest Coverage | 8.92 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 3.82 | |||||
Beneish M-Score | -2.15 | |||||
WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 11.7 | |||||
3-Year EBITDA Growth Rate | 10.5 | |||||
3-Year EPS without NRI Growth Rate | 113.5 | |||||
3-Year FCF Growth Rate | 1.3 | |||||
3-Year Book Growth Rate | 24.3 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -14.04 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 6.77 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 52.99 | |||||
9-Day RSI | 51.04 | |||||
14-Day RSI | 49.34 | |||||
3-1 Month Momentum % | -6.19 | |||||
6-1 Month Momentum % | -3.19 | |||||
12-1 Month Momentum % | 10.3 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 16.01 | |||||
Quick Ratio | 15.18 | |||||
Cash Ratio | 12.3 | |||||
Days Inventory | 166.65 | |||||
Days Sales Outstanding | 28.35 | |||||
Days Payable | 22.12 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2.6 | |||||
Shareholder Yield % | 15.91 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 79.66 | |||||
Operating Margin % | 36.95 | |||||
Net Margin % | 81.19 | |||||
EBITDA Margin % | 105.47 | |||||
FCF Margin % | 41.29 | |||||
OCF Margin % | 43.5 | |||||
ROE % | 32.64 | |||||
ROA % | 22.5 | |||||
ROIC % | 13.65 | |||||
3-Year ROIIC % | -18.6 | |||||
ROC (Joel Greenblatt) % | 720.18 | |||||
ROCE % | 29.14 | |||||
Years of Profitability over Past 10-Year | 10 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 5.12 | |||||
Forward PE Ratio | 9.1 | |||||
PE Ratio without NRI | 6.3 | |||||
Shiller PE Ratio | 8.69 | |||||
Price-to-Owner-Earnings | 3.88 | |||||
PS Ratio | 3.89 | |||||
PB Ratio | 1.24 | |||||
Price-to-Tangible-Book | 1.46 | |||||
Price-to-Free-Cash-Flow | 8.99 | |||||
Price-to-Operating-Cash-Flow | 8.95 | |||||
EV-to-EBIT | 2.74 | |||||
EV-to-EBITDA | 2.59 | |||||
EV-to-Revenue | 2.73 | |||||
EV-to-Forward-Revenue | 2.4 | |||||
EV-to-FCF | 6.21 | |||||
Price-to-GF-Value | 0.86 | |||||
Price-to-Projected-FCF | 0.44 | |||||
Price-to-Median-PS-Value | 0.86 | |||||
Price-to-Graham-Number | 0.64 | |||||
| Price-to-Net-Current-Asset-Value | 5.37 | |||||
| Price-to-Net-Cash | 13.92 | |||||
Earnings Yield (Greenblatt) % | 36.45 | |||||
FCF Yield % | 12.61 | |||||
Forward Rate of Return (Yacktman) % | -1.29 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
Innoviva Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 389.164 | ||
| EPS (TTM) (€) | 3.512 | ||
| Beta | 0.6218 | ||
| 3-Year Sharpe Ratio | 0.57 | ||
| 3-Year Sortino Ratio | 1.05 | ||
| Volatility % | 34.35 | ||
| 14-Day RSI | 49.34 | ||
| 14-Day ATR (€) | 0.254629 | ||
| 20-Day SMA (€) | 18.04 | ||
| 12-1 Month Momentum % | 10.3 | ||
| 52-Week Range (€) | 14.2 - 21.2 | ||
| Shares Outstanding (Mil) | 72.25 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Innoviva Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Innoviva Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Annual report for 2026 | 2027-02-25 | In 162 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-25 | In 162 days | ||
| Third quarter earnings results for 2026 | 2026-11-05 | In 50 days | ||
| Guidance call for 2024 | 2026-09-15 | 18.10 (+2.26%) | ||
| H.C. Wainwright 28th Annual Global Investment Conference | 2026-09-14 12:00 | 17.80 (+0.56%) | ||
| Cantor Global Healthcare Conference | 2026-09-10 08:00 | 18.10 (-0.55%) | ||
| Guidance call for 2026 | 2026-09-09 | 18.40 (+1.66%) | ||
| Second quarter earnings results for 2026 | 2026-08-05 | 18.00 (+0.56%) | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-08 13:20 | 19.50 (+3.17%) | ||
| First quarter earnings results for 2026 | 2026-05-06 | 19.50 (+0.00%) |
Show
Entries
Innoviva Inc Frequently Asked Questions
What is Innoviva Inc(FRA:HVE)'s stock price today?
The current price of FRA:HVE is €17.90. The 52 week high of FRA:HVE is €21.20 and 52 week low is €14.20.
When is next earnings date of Innoviva Inc(FRA:HVE)?
The next earnings date of Innoviva Inc(FRA:HVE) is 2026-11-05 Est..
Does Innoviva Inc(FRA:HVE) pay dividends? If so, how much?
Innoviva Inc(FRA:HVE) does not pay dividend.
Press Release
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers